Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 9;95(19):e00461-21. doi: 10.1128/JVI.00461-21

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 American Society for Microbiology.

All Rights Reserved.

PMC Copyright notice

FIG 6 — RGNNV targeting via CasRx in different grouper species. (A) Schematic representation of intracranial injection of the CasRx system in E. akaara. (B) The mRNA level of CP after intracranial injection of CasRx-dNLS and different crRNAs (CP2, RdRp2, or mix). (C) The mRNA level of RdRp after intracranial injection of CasRx-dNLS and different crRNAs (CP2, RdRp2, or mix). (D) The mRNA level of CP after intracranial injection of CasRx-NLS and different crRNAs (CP2, RdRp2, or mix). (E) The mRNA level of RdRp after intracranial injection of CasRx-NLS and different crRNAs (CP2, RdRp2, or mix). (F and G) Values indicate the cumulative mortality rate for each group of E. akaara during the 14-day experimental period after intracranial injection of CasRx-dNLS (F) or CasRx-NLS (G) with crRNAs. (H) Schematic representation of intracranial injection of the CasRx system in E. lanceolatus. (I) The mRNA level of CP after intracranial injection of CasRx-dNLS and different crRNAs (CP2, RdRp2, or mix). (J) The mRNA level of RdRp after intracranial injection of CasRx-dNLS and different crRNAs (CP2, RdRp2, or mix). (K) The mRNA level of CP after intracranial injection of CasRx-NLS and different crRNAs (CP2, RdRp2, or mix). (L) The mRNA level of RdRp after intracranial injection of CasRx-NLS and different crRNAs (CP2, RdRp2, or mix). (M and N) Values indicate the cumulative mortality rate for each group of E. lanceolatus during the 14-day experimental period after intracranial injection of CasRx-dNLS (M) or CasRx-NLS (N) with crRNAs. (O) Schematic representation of intracranial injection of the CasRx system in E. lanceolatus♂ × E. fuscoguttatus♀. (P) The mRNA level of CP after intracranial injection of CasRx-dNLS and different crRNAs (CP2, RdRp2, or mix). (Q) The mRNA level of RdRp after intracranial injection of CasRx-dNLS and different crRNAs (CP2, RdRp2, or mix). (R) The mRNA level of CP after intracranial injection of CasRx-NLS and different crRNAs (CP2, RdRp2, or mix). (S) The mRNA level of RdRp after intracranial injection of CasRx-NLS and different crRNAs (CP2, RdRp2, or mix). (T and U) Values indicate the cumulative mortality rate for each group of E. lanceolatus♂ × E. fuscoguttatus♀ during the 14-day experimental period after intracranial injection of CasRx-dNLS (T) or CasRx-NLS (U) and crRNAs. (V) Schematic representation of intracranial injection of the CasRx system in E. lanceolatus♂ × E. radiatus♀. (W) The mRNA level of CP after intracranial injection of CasRx-dNLS and different crRNAs (CP2, RdRp2, or mix). (X) The mRNA level of RdRp after intracranial injection of CasRx-dNLS and different crRNAs (CP2, RdRp2, or mix). (Y) The mRNA level of CP after intracranial injection of CasRx-NLS and different crRNAs (CP2, RdRp2, or mix). (Z) The mRNA level of RdRp after intracranial injection of CasRx-NLS and different crRNAs (CP2, RdRp2, or mix). (a and b) Values indicate the cumulative mortality rate for each group of E. lanceolatus♂ × E. radiatus♀ during the 14-day experimental period after intracranial injection of CasRx-dNLS (a) or CasRx-NLS (b) with crRNAs. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.